Berry Genomics Awaits CFDA Approval of Noninvasive Prenatal Test

Berry Genomics of Beijing is seeking CFDA approval for its noninvasive prenatal test, which runs on a customized Illumina NextSeq 500 sequencer. The two companies co-developed the sequencer. Berry Genomics’ Bambni™ assay, which has completed more than 200,000 samples, includes a unique PCR-free library prep technology and proprietary RUPA™ analysis software. Berry said it is in late-stage review at the CFDA. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //